Results 91 to 100 of about 63,359 (335)

Higher secant varieties of $\mathbb{P}^n \times \mathbb{P}^m$ embedded in bi-degree $(1,d)$ [PDF]

, 2010
Let $X^{(n,m)}_{(1,d)}$ denote the Segre-Veronese embedding of $\mathbb{P}^n \times \mathbb{P}^m$ via the sections of the sheaf $\mathcal{O}(1,d)$. We study the dimensions of higher secant varieties of $X^{(n,m)}_{(1,d)}$ and we prove that there is no ...
Bernardi, Alessandra, Carlini, Enrico, Catalisano, Maria Virginia   +2 more
core   +6 more sources

Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML.

Blood Advances, 2020
Isocitrate dehydrogenase (IDH) 1 and 2 mutations result in overproduction of D-2-hydroxyglutarate (2-HG) and impaired cellular differentiation. Ivosidenib, a targeted mutant IDH1 (mIDH1) enzyme inhibitor, can restore normal differentiation and results in
S. Choe, Hongfang Wang, C. Dinardo, E. Stein, S. de Botton, G. Roboz, J. Altman, A. Mims, J. Watts, D. Pollyea, A. Fathi, M. Tallman, H. Kantarjian, R. Stone, L. Quek, Z. Konteatis, L. Dang, Brandon Nicolay, Parham Nejad, Guowen Liu, V. Zhang, Hua Liu, M. Goldwasser, Wei Liu, K. Marks, C. Bowden, S. Biller, E. Attar, Bin Wu   +28 more
semanticscholar   +1 more source

Mutant IDH1 and seizures in patients with glioma [PDF]

Neurology, 2017
Because the d-2-hydroxyglutarate (D2HG) product of mutant isocitrate dehydrogenase 1 (IDH1mut) is released by tumor cells into the microenvironment and is structurally similar to the excitatory neurotransmitter glutamate, we sought to determine whether IDH1mut increases the risk of seizures in patients with glioma, and whether D2HG increases the ...
Chen, Hao, Judkins, Jonathon, Thomas, Cheddhi, Wu, Meijing, Khoury, Laith, Benjamin, Carolina G, Pacione, Donato, Golfinos, John G, Kumthekar, Priya, Ghamsari, Farhad, Chen, Li, Lein, Pamela, Chetkovich, Dane M, Snuderl, Matija, Horbinski, Craig   +14 more
openaire   +4 more sources

Correlation of IDH1 mutation with clinicopathologic factors and prognosis in primary glioblastoma: a report of 118 patients from China. [PDF]

PLoS ONE, 2012
It has been reported that IDH1 (IDH1R132) mutation was a frequent genomic alteration in grade II and grade III glial tumors but rare in primary glioblastoma (pGBM).
Wei Yan, Wei Zhang, Gan You, Zhaoshi Bao, Yongzhi Wang, Yanwei Liu, Chunsheng Kang, Yongping You, Lei Wang, Tao Jiang   +9 more
doaj   +1 more source

Association of TP53 Alteration with Tissue Specificity and Patient Outcome of IDH1-Mutant Glioma

Cells, 2021
Since the initial discovery of recurrent isocitrate dehydrogenase 1 (IDH1) mutations at Arg132 in glioma, IDH1 hotspot mutations have been identified in cholangiocarcinoma, chondrosarcoma, leukemia, and various other types of cancer of sporadic incidence.
Balazs Murnyak, L. Eric Huang
doaj   +1 more source

Oncogenic R132 IDH1 Mutations Limit NADPH for De Novo Lipogenesis through (D)2-Hydroxyglutarate Production in Fibrosarcoma Sells. [PDF]

, 2018
Neomorphic mutations in NADP-dependent isocitrate dehydrogenases (IDH1 and IDH2) contribute to tumorigenesis in several cancers. Although significant research has focused on the hypermethylation phenotypes associated with (D)2-hydroxyglutarate (D2HG ...
Badur, Mehmet G, Cordes, Thekla, Guan, Kun-Liang, Ma, Shenghong, Magana, Jose H, McBrayer, Samuel K, Metallo, Christian M, Muthusamy, Thangaselvam, Parker, Seth J   +8 more
core  

A DIA‐MS‐based proteomics approach to find potential serum prognostic biomarkers in glioblastoma patients

Molecular Oncology, EarlyView.
A DIA‐MS‐based proteomics analysis of serum samples from GB patients and healthy controls showed that high levels of IL1R2 and low levels of CRTAC1 and HRG in serum are associated with poor survival outcomes for GB patients. These circulating proteins could serve as biomarkers for the prediction of outcome in patients with GB.
Anne Clavreul, François Guillonneau, Odile Blanchet, Hamza Lasla, Audrey Rousseau, Catherine Guette, Alice Boissard, Cécile Henry, Morgan Dhondt, Pascal Jézéquel, Philippe Menei, Jean‐Michel Lemée   +11 more
wiley   +1 more source

cyTRON and cyTRON/JS: two Cytoscape-based applications for the inference of cancer evolution models

, 2017
The increasing availability of sequencing data of cancer samples is fueling the development of algorithmic strategies to investigate tumor heterogeneity and infer reliable models of cancer evolution.
D Ramazzotti, D Ramazzotti, D Ramazzotti, G Caravagna, L De Sano, LO Loohuis, M Antoniotti, MD Wilkinson, P Shannon, PC Nowell, S Turajlic   +10 more
core   +1 more source

An Analysis for IDH‐Mutant Grade 4 Astrocytoma Based on WHO CNS 5: Implication of Clinical Practice

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Purpose There is ongoing debate regarding the therapeutic approach and prognosis for IDH‐mutant grade 4 astrocytoma, a newly defined subtype of diffuse glioma in the 2021 WHO classification system for central nervous system tumors (WHO CNS 5). The aim of this study was to explore the clinical outcome and prognosticators for newly diagnosed IDH‐
Xianxin Qiu, Liping Liang, Lingchao Chen, Pengjie Hong, Wanzun Lin, Jiabing Liu, Zhirui Zhou, Wenjia Zhu, Tianqi Wu, Mingyuan Pan, Yihua Zhong, Jing Gao, Zhiyong Qin, Yang Wang   +13 more
wiley   +1 more source

Nanomedicine‐Driven Modulation of Reductive Stress for Cancer Therapy

Advanced Science, EarlyView.
This article introduces a novel therapeutic paradigm that deliberately induces reductive stress within tumor cells to exploit their unique biochemical vulnerabilities. It systematically reviews the underlying biological mechanisms, current detection and monitoring techniques, and emerging advanced nanotechnology platforms specifically designed to ...
Yumin Mao, Xianping Liu, Xu Chu, Feixiang Chen, Ruicheng Shi, Zonghao Liu, Yelin Wu, Yanyan Liu, Wenbo Bu   +8 more
wiley   +1 more source